- Home
- CBRL vs BBOT Comparison
CBRL vs BBOT Comparison
Compare CBRL & BBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CBRL | BBOT |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 764.9M | 717.8M |
| IPO Year | 1998 | 2024 |
Fundamental Metrics
Financial Performance| Metric | CBRL | BBOT |
|---|---|---|
| Price | $58.30 | $9.63 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | ★ $36.89 | $24.00 |
| AVG Volume (30 Days) | ★ 813.8K | 254.2K |
| Earning Date | 06-04-2026 | 05-26-2026 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | 12.57 | ★ 99.93 |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $3,030,445,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.56 | N/A |
| P/E Ratio | $67.65 | ★ N/A |
| Revenue Growth | ★ 3.56 | N/A |
| 52 Week Low | $24.85 | $7.00 |
| 52 Week High | $63.15 | $14.87 |
Technical Indicators
Market Signals| Indicator | CBRL | BBOT |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 60.86 |
| Support Level | $26.91 | $7.99 |
| Resistance Level | $59.67 | $11.02 |
| Average True Range (ATR) | 2.16 | 0.48 |
| MACD | -0.23 | 0.02 |
| Stochastic Oscillator | 68.44 | 87.94 |
Price Performance
Historical ComparisonAbout CBRL Cracker Barrel Old Country Store Inc
Cracker Barrel Old Country Store Inc operates hundreds of full-service restaurants throughout the United States. The Cracker Barrel stores consists of a restaurant with a gift shop. The restaurants serve breakfast, lunch and dinner. The gift shop offers a variety of decorative and functional items specializing in rocking chairs, holiday gifts, toys, apparel and foods.
About BBOT BridgeBio Oncology Therapeutics Inc.
BridgeBio Oncology Therapeutics Inc, is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes. The Company operates in one operating and reportable segment within the United States, developing oncology therapies through various related development projects.